Early participant reported symptoms as predictors of adherence to anastrozole in the International Breast Cancer Intervention Studies II

- Sestak, I., Smith, S. G., Howell, A., Forbes, J. F., Cuzick, J.

Observation versus late reintroduction of letrozole as adjuvant endocrine therapy for hormone receptorpositive breast cancer (ANZ0501 LATER): an open-label randomised, controlled trial

- Zdenkowski, N., Forbes, J. F., Mann, G. B., Coates, A. S., Gebski, V., Davies, L., Thornton, R., Reaby, L., Cuzick, J., Green, M., Boyle, F. M., Kannourakis, G., Gill, P. G., Bayliss, E., Saunders, C., Della-Fiorentina, S., Kling, N., Campbell, I.

Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials

- Dowsett, M., Forbes, J. F., Dubsky, P., Gnant, M., Kaufmann, M., Kilburn, L., Perrone, F., Rea, D., Thuerlimann, B., van de Velde, C., Pan, H., Peto, R., Bradley, R., Ingle, J., Aihara, T., Bliss, J., Boccardo, F., Coates, A., Coombes, R. C., Cuzick, J.

Improving decision making about clinical trial participation - a randomised controlled trial of a decision aid for women considering participation in the IBIS-II breast cancer prevention trial

- Juraskova, I., Butow, P., Bonner, C., Bell, M. L., Smith, A. B., Seccombe, M., Boyle, F., Reaby, L., Cuzick, J., Forbes, J. F.

Relationships between CYP2D6 phenotype, breast cancer and hot flushes in women at high risk of breast cancer receiving prophylactic tamoxifen: results from the IBIS-I trial

- Sestak, I., Kealy, R., Nikoloff, M., Fontecha, M., Forbes, J. F., Howell, A., Cuzick, J.

A new pathological system for grading DCIS with improved prediction of local recurrence: results from the UKCCCR/ANZ DCIS Trial

- Pinder, S. E., Duggan, C., Ellis, I. O., Cuzick, J., Forbes, J. F., Bishop, H., Fentiman, I. S., George, W. D.